Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine
Viruses · 2024
DOI: 10.3390/v16111715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Pavithra Nagarajan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Rilpivirine, HIV-1, HIV Infections, Drug Resistance, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Introduction
Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV).
Methods
We analyzed pooled HIV-1 RT genotypic data from 280 PLWH in the multicenter EuResist database and 115 PLWH in the Stanford HIV Drug Resistance Database (HIVDB) who received RPV as their only NNRTI.
Results
Among the 395 PLWH receiving RPV, 180 (45.6%) had one or more NNRTI-associated DRMs. Overall, 44 NNRTI-associated DRMs were identified, including 26 that occurred in two or more PLWHs. Seven mutations had a prevalence ≥10% among the 180 PLWH with one or more NNRTI-associated DRM: E138K (32.2%), V90I (25.0%), K101E (17.8%), Y181C (17.2%), E138A (13.9%), H221Y (12.2%), and K103N (10.6%). Y181C was significantly more likely to co-occur with K101E, V179F, H221Y, and M230L. Ten novel non-polymorphic mutations at known NNRTI-associated mutation positions were also identified, usually in just one PLWH: L100F, V108A, T139I, P225S, M230V, Y232C, and T240A/I/M/S.
Conclusions
Our analysis extends the spectrum of mutations emerging in PLWH receiving RPV. Additional phenotypic characterization of RPV-selected mutations is necessary to better understand their biological and possible clinical significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
- EuResist Network GEIE, 00152 Rome, Italy.
- Department of Information Engineering, University of Pisa, 56122 Pisa, Italy.
- InformaPRO S.r.l., 00152 Rome, Italy.
- Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg.
- Institute of Virology, University of Cologne, 50931 Cologne, Germany.
ORCID-Profile: Giulia Di Teodoro, Francesca Incardona, Carole Seguin-Devaux, Rolf Kaiser, Ana B Abecasis, Perpetua Gomes, Kaiming Tao, Maurizio Zazzi, Robert W Shafer
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Nagarajan, P., Zhou, J., Di Teodoro, G., Incardona, F., Seguin-Devaux, C., Kaiser, R., Abecasis, A. B., Gomes, P., Tao, K., Zazzi, M., Shafer, R. W., & EuResist Network (2024). Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine. Viruses. https://doi.org/10.3390/v16111715
Vancouver
Nagarajan P, Zhou J, Di Teodoro G, Incardona F, Seguin-Devaux C, Kaiser R, et al. Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine. Viruses. 2024. doi:10.3390/v16111715
BibTeX
@article{Nagarajan2024,
author = {Nagarajan, Pavithra and Zhou, Jinru and Di Teodoro, Giulia and Incardona, Francesca and Seguin-Devaux, Carole and Kaiser, Rolf and Abecasis, Ana B and Gomes, Perpetua and Tao, Kaiming and Zazzi, Maurizio and Shafer, Robert W and EuResist Network, EuResist Network},
title = {Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16111715}
}
EUVIMED